News

Biocon's planned CRO IPO could change the tone in India

Biocon, India's pre-eminent biotech company, is planning to spin out its in-house CRO in an Indian IPO, a move that shines a light on the country's evolving industry.

Catalent boosts its profits despite some flat revenue

Catalent came through with a big earnings boost last quarter, shaking off some deleterious currency fluctuations and cutting costs.

Canadian CRO JSS buys its way into India with latest deal

Montreal-headquartered CRO JSS Medical Research is reaching into India, buying out Max Neeman International as it expands around the globe.

Quintiles beefs up in bioanalytics ahead of Quest partnership

Awaiting the closure of a wide-ranging deal with Quest Diagnostics, Quintiles is expanding its capabilities in bioanalytics, opening a new outpost in Europe for lab tests.

AMRI swings to another loss despite big sales gains

Contract drug developer AMRI, on the mend after a series of setbacks, posted a 38% sales boost to start the year, but the costs of an ongoing transition dragged it into the red for yet another quarter.

Parexel trims its ambitions after a flat quarter

CRO giant Parexel posted flat revenue last quarter, paring back its full-year expectations in the face of currency headwinds and client delays.

Allergan picks CRO ImageIQ for bladder trial

Allergan has reached out to CRO ImageIQ to support its development of a new treatment for bladder disease, recruiting the imaging specialist to pitch in on a new clinical trial.

WuXi's CEO moves to take the CRO private

WuXi PharmaTech's CEO has teamed up with a major investor in an attempt to take the CRO private, pitching a buyout that would give the Chinese company's shareholders a 16.2% premium.

Charles River ticks up its revenue amid a shift in focus

Preclinical research giant Charles River Laboratories posted 7% revenue growth in the first quarter, absorbing the blow of a tough currency translation as it deepens its focus on drug discovery services.

Quintiles scales back its 2015 projections after a mixed quarter

Quintiles' banner business came up short in the first quarter, as currency fluctuations bit into revenue and led the world's largest CRO to dial down its full-year guidance.

Icon dampens its outlook despite a strong quarter

Icon came through with double-digit revenue growth in the first quarter, but currency fluctuations have the Irish CRO scaling back its expectations for the full year.

INC swings to profit and dials up its revenue expectations

CRO INC Research boosted its sales by 14.5% in the first quarter, returning to profitability as it blueprints a big year.

BioClinica recruits a new eClinical president amid rapid expansion

BioClinica has poached an Oracle exec to lead its banner eClinical division, part of its long-term expansion efforts.

WuXi deepens its genomic ties with latest partnership

Months removed from buying its way into the world of Big Data genomics, Chinese CRO WuXi PharmaTech has partnered up with DNAnexus to take its technology to the cloud.

India's Biocon eyes an IPO for its in-house CRO

Indian biotech giant Biocon is planning to take Syngene, its in-house CRO, public in an IPO on the local exchange.

Sartorius snags U.K. CRO BioOutsource with an eye on biosimilars

Biopharma production specialist Sartorius Stedim Biotech has acquired BioOutsource, a U.K. CRO focused on the growing demand for knockoffs of top-selling biologics.

PPD reaches into China with a new central lab

PPD has opened a new central lab facility in Shanghai, expanding its testing services into China as it stretches out around the globe.

Catalent wraps up a $52M manufacturing expansion

Catalent doubled its capacity at a Kentucky manufacturing facility, wrapping up a $52 million project with plans to add about 140 new workers.

Quintiles deepens its Latin American ties with Argentine partnership

Quintiles is further entrenching itself in Latin America, striking a deep-rooted alliance with a research site in Buenos Aires to widen its global network of trusted partners.

Recipharm bets on a U.S. biotech with an R&D joint venture

Swedish contract drug developer Recipharm has signed a deal with Virginia's Synthonics, investing in the biotech and lending its expertise in the development of new compounds.